cbdMD, Inc., a nationally recognized consumer cannabidiol (CBD) brand (NYSE American: YCBD), has been named a “Brand to Watch” by Brightfield Group, a leading cannabis research firm. In their recent mid-year 2019 Market Update, Brightfield Group ranked cbdMD in the top 10 of domestic CBD companies in two categories, Topicals and Skincare/Beauty.
“There is a massive shakeup in the CBD industry with smart, savvy companies effectively leveraging marketing and PR to disrupt the previous leaders,” said Bethany Gomez, Brightfield Group’s Managing Director. “cbdMD has leveraged high profile sponsorships better than anyone to rapidly gain a massive consumer base and break into the top 20 CBD companies in the country.”
“In just 18 months, cbdMD has gone from start up to being an innovative, industry leader,” said Marty Sumichrast, cbdMD Co-founder and Chairman. “We’re pleased the highly respected Brightfield Group recognized us as a ‘Brand To Watch’ in their recent post.”
In a July 8 post titled, “Brand To Watch: cbdMD,” the Brightfield Group dug into why cbdMD stands out in the CBD category where new brands and products are launching everyday. The report found that cbdMD’s strategic partnerships in sports and fitness, coupled with its charitable efforts, have all contributed to its continued rise in the CBD industry.
In part, the post stated, “Trend followers should look to emulate cbdMD’s efforts, using creativity and strategy to move forward – despite hurdles presented by often outdated or misinformed advertising and marketing policies – and effectively reach target consumers who otherwise would not know about nor seek out CBD products.”
“What we’ve been able to do over the past few years is incredible,” said Caryn Dunayer, President of cbdMD. “As the report mentions, traditional forms of advertising in the space is limited. Our strategic partnerships have afforded us a unique opportunity to grow the brand and rapidly gain market share in an increasingly saturated space.”
In addition to being the first CBD company listed on the NYSE-American (YCBD), cbdMD is the official founder of National CBD Day (August 8) and National Hemp Day (February 4). In April, cbdMD became the first CBD company to sponsor a major professional sports league, the BIG3, and has maintained its recurring partnership with Nitro Circus. Team cbdMD is made up of Bubba Watson, Lolo Jones, Kerri Walsh Jennings, Chad ReedQuinton “Rampage” Jackson, Ryan Sheckler, Tyron Woodley, Michael Bisping, Vicki Golden, Ken Block, and more.
The full post from Brightfield Group can be read here: https://www.brightfieldgroup.com/post/cbdmd-brand-watch-cbd-partnerships
To learn more about cbdMD and their comprehensive line of U.S.A. organically grown, THC-free CBD products, please visit: www.cbdmd.com
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2018 as filed with the Securities and Exchange Commission (the “SEC”) on December 12, 2018, our Quarterly Report on Form 10-Q for the period ended March 31, 2019 as filed with the SEC on May 15, 2019 and our other filings with the SEC. . All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.
Global Alliance for Cannabis Commerce Announces Nationwide “GACC Certified™” Testing and Purity Standards Program for Cannabis Products; Responds to Vape-Related Illness Outbreak
The Global Alliance for Cannabis Commerce (GACC), a trade organization representing a major cross-section of the global cannabis industry, today announced the launch of a nationwide, voluntary industry certification standard for safety and purity in cannabis product testing. It is expected by the end of 2020 this program will be available to all state-licensed cannabis operations. It gives licensed sellers and consumers confidence that the legal products that are approved under this program meet accepted safety and purity standards and are genuine. The standards and testing protocols are expected to meet or exceed the most stringent state standards currently in effect.
“Current laws make it impossible to assure the public that in every one of the 33 states where cannabis has been legalized, that there are uniform accepted standards for safety and purity even though consumers may well use legal product when in different states. Until federal law is corrected this problem will continue to exist,” said Randal John Meyer, Executive Director at GACC.
“GACC wants to establish a means by which consumers can have confidence in the products they buy and to provide industry the tools to give this assurance. Members will have access to a coordinated national network of ISO certified laboratories that will use scientifically sound and accepted test methods to assure that cannabis meets the most appropriate safety and purity standards,” said GACC President Rezwan Khan. “By the end of next year, cannabis consumers will be able to look at a participating product anywhere in the United States that it is legally sold, see our blue leaf, and know if it meets the rigorous standard of GACC Certified™ consumer safety testing.”
GACC and each of its member companies believes that absent changes in federal law, it is incumbent on industry to establish consensus industry standards for safety and purity, and to create a serious and effective testing program.
Nominations for membership on the Standards Committee (terms are two years) will be open to the public beginning on Thursday, December 5, 2019, and closing on January 30, 2020. The Board of GACC will determine the initial composition. Future members will include public nominations and will be determined by the GACCAST Standards Committee and reviewed by the GACC Board of Directors. It is expected that the GACCAST Standards Committee will take approximately nine months to establish the initial standards and protocols so that implementation can begin in 2020.
All current GACC members have pledged to support the development of this standards setting protocol and to adopt and implement it as well when it is effective. This includes brands such as Raw Garden, DNA Genetics, Crockett Family Farms, Urbn Leaf, La Familia, and Team Elite Genetics, and all derivative cannabis products from DNA Genetics’ and Crockett Family Farms’ genetics.
To accommodate the entire legal cannabis industry’s access to this program, GACC will be creating a new, membership class, the Standard Membership, that will involve minimal costs for participation, and that will provides access to the GACC Certified™ Program. Interested companies may inquire through the GACC website here: https://globalcannabiscommerce.org/gacc-certifiedtm/. GACC is also planning to arrange for testing discounts for members who use the GACC network of laboratories.
GACC President Rezwan Khan added, “Our goal is to ensure this program isn’t cost-prohibitive for any cannabis companies of any size. Cannabis has needed a voluntary unifying force for safety certification for years to increase consumer confidence in its products. Well, here it is—with a number of major cannabis brands already pledging widespread adoption.”
GACC has previously partnered with solo Sciences to ensure that medical patients and adult consumers do not unwittingly purchase counterfeit or illicit vape products. Through the partnership, solo sciences will be offering GACC members a substantial discount on anti-counterfeiting, instant product recall solo*CODE™ technology. “The combination of the voluntary GACC Certified™ consumer safety standard, particularly when combined with members’ access to substantially discounted solo*CODE™ anticounterfeiting technology, allows GACC members to provide their consumers with the confidence they need that anywhere in the United States they legally purchase a participating cannabis product, our blue leaf means it’s safe and genuine,” said GACC Executive Director Randal John Meyer.
SOURCE Global Alliance for Cannabis Commerce
Dixie Brands’ Wholly-Owned Subsidiary Secures Patent for Scientific Breakthrough in Cannabinoid Delivery
Dixie Brands Inc. (“Dixie” or “the Company”) (CSE: DIXI.U), (OTCQX: DXBRF), (Frankfurt: 0QV), one of the cannabis industry’s leading consumer packaged goods (“CPG”) companies, today announced that the United States Patent and Trademark Office will issue its wholly-owned subsidiary, Aceso Wellness, LLC (“Aceso”), a patent for a unique range of formats providing for the delivery of cannabinoids, along with nutrients, in effervescent powder and/or aqueous liquid forms.
The patent application, entitled ‘Cannabinoid Emulsion Product and Process for Making the Same’, encompasses a broad set of popular formats and formulations that provide for various nutraceutical compositions including cannabinoids, supplements and vitamins. These compositions have been configured for specific uses such as the promotion of the immune system, improved energy levels, joint and bone health, reduced inflammation, and more efficient cellular energy metabolism.
“This patent is the culmination of a 3-year process and demonstrates our commitment to, and investment in, the potential power of the inclusion of cannabinoids to help support healthy lifestyles.” says Jay Denniston C.F.S., Director of Science, Dixie Brands. “It provides proven, efficacious formats for consumers as they continue to explore cannabis as a plant-based, healthy alternative to traditional pharmaceutical products.”
The Company’s patented technology provides an extensive and protected platform to further access the burgeoning US Dietary Supplement market in addition to the rapidly emerging hemp-derived category. The US Dietary Supplement market is expected to grow to nearly US$57 billion by 2024 (Source: Matej Mikulic, Sep 19, 2019) lead by non-pill formats and fueled by increasing consumer awareness of nutrition, a focus on preventative health care and a desire for solutions that are perceived to be more natural.
“This is an incredibly exciting development for Dixie Brands, reflecting the depth of our R&D heritage, established over nearly a decade.” said Chuck Smith, President and CEO, Dixie Brands. “As the FDA provides positive guidance and the category continues to grow, securing patents for our scientific intellectual property not only provides protection for key elements of our portfolio and optimizes shareholder value but also further supports the continued legitimization and normalization of the cannabis industry.”
The patented technology has been commercialized by Aceso’s range of hemp-derived sprays, dissolvable tablets and powder sachets. The effervescent powder lies at the center of the company’s growth strategy in the hemp-derived CBD market due to the existing popularity of that format in the broader health and wellness category. The portfolio currently includes Calm, Soothe and Wellness variants and is available in more than 1,000 brick and mortar stores across the country. The breadth of the forthcoming patent protects the inclusion of cannabinoids in products across a broader range of formats and channels including the regulated cannabis marketplace.
SOURCE Dixie Brands, Inc.
Avicanna Receives DTC Eligibility for Common Shares on OTCQX
Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has obtained eligibility with the Depository Trust Company (“DTC“) for its common shares listed in the United States on the OTCQX® Best Market.
DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered to be “DTC eligible”. DTC eligibility is expected to simplify the process of trading the Company’s common shares on the OTCQX Best Market and enhance liquidity for U.S. Investors.
“With our common stock listed in the U.S. now DTC eligible, a greater number of brokerages and trading platforms will be able to manage trades in our shares. This increased accessibility for investors is expected to improve the liquidity of our shares, which will also help to attract more investors that are following the exciting momentum we are building in our business as we execute on our commercialization strategy,” stated Setu Purohit, President.
SOURCE Avicanna Inc.
Cannabis4 weeks ago
Supreme Cannabis First Quarter Earnings Release Scheduled for November 14, 2019
Cannabis4 weeks ago
Addressing THC Detox Myths and Facts
Cannabis4 weeks ago
Cannabis Can Treat Epileptic Seizures
Cannabis3 weeks ago
Khiron Launches Kuida Brand in the US, Begins First Sales
Cannabis4 weeks ago
Simplifya Takes the Guesswork Out of Cannabis M&A
Cannabis4 weeks ago
Mastercard partners with Tappy Technologies to Embed Payment Functionality into Fashion Wearables
Cannabis4 weeks ago
dosist™ Announces Strategic Domestic Expansion Bringing Dose-Controlled Cannabis Products to its Second Adult-Use Market
Cannabis4 weeks ago
Medicinal cannabis company Cronos Australia makes ASX debut